Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)
December 20, 2025 — Moderna, Inc. (NASDAQ: MRNA) is ending the year in classic Moderna fashion: a tug-of-war between near-term uncertainty (COVID policy and demand) and long-term optionality (a pipeline that still wants to be the sequel to the pandemic-era